CORE--CLINICAL PHARMACOLOGY/ANALYTICAL CHEMISTRY

核心--临床药理学/分析化学

• 批准号: 6354097
• 负责人: RICHARD TIDWELL
• 金额: $ 24.4万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-08-01 至 2001-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6354097
• 关键词: AIDS; AIDS therapy; HIV infections; analytical chemistry; antiAIDS agent; biomedical facility; capillary electrophoresis; drug interactions; drug metabolism; drug screening /evaluation; gas chromatography; high performance liquid chromatography; human tissue; mass spectrometry; microorganism disease chemotherapy; nuclear magnetic resonance spectroscopy; opportunistic infections; pharmacokinetics

The purpose of Core I will be to provide a centralized unit to facilitate pharmacological and analytical studies of AIDS-related clinical and basic science research at UNC-CH and Research Triangle Institute. To accomplish this goal we propose to bring together a group of established investigators, collaborators, and advisors in analytical chemistry. The services provided to the AIDS investigators by the Core will include: specimen procurement and handling of HIV infected and non-infected material; pharmacology consultation and support and support; and the analysis of samples. The analyses will be conducted in a state of the art analytical laboratory that includes high performance liquid chromatography, gas chromatography, capillary electrophoresis nuclear magnetic resonance spectroscopy, and mass spectrometry. The laboratory will be centrally located and have convenient access for the AIDS investigators at UNC-CH. In the absence of the proposed facility important drug assays or other pharmacological studies were either performed by individual investigators, contracted to private firms, or bypassed for lack of funding. The proposed Core should fill all of the analytical and pharmacology needs of AIDS researchers without undue financial burden on their primary grants. In addition, the easy availability of this facility will stimulate new and important AIDS-related drug research. A partial listing of potential projects for the Core, based on current expressed needs of AIDS researchers at UNC-CH and RI, include: 1.) To develop and carry out accurate, sensitive, and specific measurements performed under GLP standards for non-clinical laboratory studies, or drugs used to treat retroviral infection and AIDS-related opportunistic infections. The assays will determine drug concentrations in blood, plasma, cerebrospinal fluid, seminal plasma, urine respiratory fluids, and tissues. 2). To perform pharmacokinetic analysis of drug concentrations in Phase I/II drug development investigators of AIDS-related agents, in drug interaction protocols in specific patient population. 3) To evaluate pharmacodynamic effects of measured rug concentrations. 4) To design and implement original pharmacokinetic/pharmacodynamic research in patients with HIV infections. 5) To provide analytic and pharmacokinetic support of preclinical metabolism studies of novel pro-drugs for treatment of opportunistic infections.

核心I的目的是提供一个中央单位， 艾滋病相关的临床和基础药理学和分析研究 UNC-CH和三角研究所的科学研究。完成 我们建议将一组已建立的 分析化学领域的研究者、合作者和顾问。的 核心小组向艾滋病调查人员提供的服务将包括： 艾滋病毒感染者和非感染者的标本采集和处理 材料;药理学咨询和支持和支持;以及 样品分析。分析将在最先进的技术水平下进行 分析实验室，包括高性能液体 色谱法、气相色谱法、毛细管电泳法 磁共振光谱和质谱。实验室 将位于市中心，并有方便的艾滋病 由于没有拟议的设施， 药物测定或其他药理学研究由 个别调查人员，承包给私营公司，或绕过， 缺乏资金。拟议的核心小组应填补所有分析和 艾滋病研究人员的药理学需求，而不会造成不必要的经济负担， 他们的主要赠款。此外，该设施的便利性 将刺激新的和重要的艾滋病相关药物研究。 根据目前的情况， UNC-CH和RI的艾滋病研究人员表示的需求包括：1.到 开发并执行准确、灵敏和具体的测量 根据GLP标准进行非临床实验室研究，或 用于治疗逆转录病毒感染和艾滋病相关机会性感染的药物 感染.该分析将确定血液中的药物浓度， 血浆、脑脊液、精浆、尿呼吸道液，以及 组织中2）。进行药物浓度的药代动力学分析， 艾滋病相关药物的I/II期药物开发研究者，在药物 特定患者人群的交互协议。3)评价 测定的rug浓度的药效学效应。4)设计和 在患者中实施原创药代动力学/药效学研究 艾滋病毒感染者。5)提供分析和药代动力学支持， 用于治疗糖尿病的新型前药的临床前代谢研究 机会性感染